Enzymatic or chemical modifications in RNA have been shown to dramatically alter the way our genetic code is translated. Cells utilise these epitranscriptomic modifications to modify their metabolism, structure and viability in response to extracellular cues and various stressors. Adenosine residues in RNA are most targeted for modification and can undergo for example, methylation or deamination. The resulting N-6-methyl-adenosine (m6A) and adenosine-to-inosine (A-to-I) editing, respectively, have been associated with cardiovascular disease. The Ischemic Heart Disease Epitranscriptomics and Biomarkers (IHD-EPITRAN) study hypothesis states that the pathological features of IHD are mirrored in circulating cellular or extracellular epitranscriptomes. The study focuses on m6A modifications as well as A-to-I editing in blood RNA.